ArticleNature communications2020
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.Gynecologic oncology · 2024Trial
- Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor.BMC cancer · 2026Article
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.Nature communications · 2025Article
- 5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma.EMBO molecular medicine · 2025Article
- A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research.Cancer medicine · 2025Article
- Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma.Human cell · 2025Article
- Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial Carcinoma.JCO precision oncology · 2025Article
- Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.Cancer research and treatment · 2024Article
- The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.Nature communications · 2024Article
- Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.Science advances · 2023Article
- [Precision oncology options in urological cancers].Urologie (Heidelberg, Germany) · 2023Review
- Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.In vitro models · 2023Review
- KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.Cancer research · 2023Article
- Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome geneBMJ oncology · 2023Article
- Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models.Journal of the National Cancer Center · 2022Review
- Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.BMC medical genomics · 2022Article
- Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.Frontiers in oncology · 2022Article
- Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
37 authors at 4 institutions in 2 countries.
Kwanghee Kim *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0003-0544-6792
Wenhuo Hu *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-8686-7160
François AudenetUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0001-5722-2075
Nima AlmassiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Aphrothiti J HanrahanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Katie MurrayUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-2633-9438
Aditya BagrodiaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Nathan WongUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Timothy N ClintonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-0616-6840
Shawn DasonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Vishnu MohanDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, 7610001, Israel.
Sylvia JebiwottDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Karan NagarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Jianjiong GaoMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Alex PensonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0003-2429-2370
Chris HughesDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Benjamin GordonDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-3856-0500
Ziyu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Yiyu DongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Philip A WatsonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Ricardo AlvimDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Arijh ElzeinHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Sizhi P GaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Emiliano CoccoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Alessandro D SantinGynecology & Reproductive Sciences, Department of Obstetrics, Yale University School of Medicine, New Haven, CT, 06510, USA.
Irina OstrovnayaDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10017, USA.
James J HsiehMolecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, 63110, USA.ORCID http://orcid.org/0000-0003-3595-0551
Irit SagiDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, 7610001, Israel.
Eugene J PietzakUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-0930-8824
Jonathan E RosenbergGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Gopa IyerGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-5093-6099
Herbert A VargasBody Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Maurizio ScaltritiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-5522-1447
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-2938-6627
David B SolitHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. solitd@mskcc.org.ORCID http://orcid.org/0000-0002-6614-802X
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. colemanj@mskcc.org.
Memorial Sloan Kettering Cancer Center · USWeizmann Institute of Science · ILWashington University in St. Louis · USYale University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BAJORIN, DEAN F. · 2018 to 2024
$11.8MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MProject 3: Modeling tumor evolution and drug response in bladder cancer organoidsP01CA221757 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEN, MICHAEL M. · 2018 to 2022
$8.6MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MUROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MDevelopment of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutationsR01CA229624 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2018 to 2022
$2.0MNCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA184746NCI NIH HHS P01 CA221757NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS R01 CA229624NCI NIH HHS R01 CA234361NCI NIH HHS T32 CA082088NIH HHS U54 OD020355
Abstract
Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molecular characteristics. The advancement of UTUC research is hampered by the lack of disease-specific models. Here, we report the establishment of patient derived xenograft (PDX) and cell line models that reflect the genomic and biological heterogeneity of the human disease. Models demonstrate high genomic concordance with the corresponding patient tumors, with invasive tumors more likely to successfully engraft. Treatment of PDX models with chemotherapy recapitulates responses observed in patients. Analysis of a HER2 S310F-mutant PDX suggests that an antibody drug conjugate targeting HER2 would have superior efficacy versus selective HER2 kinase inhibitors. In sum, the biological and phenotypic concordance between patient and PDXs suggest that these models could facilitate studies of intrinsic and acquired resistance and the development of personalized medicine strategies for UTUC patients.
Indexed as
Gene Expression Regulation, NeoplasticAgedAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiopsyCamptothecinCarcinoma, Transitional CellFemaleGene Expression ProfilingGenetic VariationHigh-Throughput Nucleotide SequencingHumansImmunoconjugatesInterleukin Receptor Common gamma SubunitMaleAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCamptothecinIl2rg protein, mouseImmunoconjugatesInterleukin Receptor Common gamma SubunitneratinibQuinolinesTrastuzumabtrastuzumab deruxtecan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.